Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with debilitating diseases. The company's initial in vitro diagnostic test, OVA1®, was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a second generation OVA1 test with significantly improved specificity and ease of use and which uses widely distributed platforms. For additional information, including published clinical trials, visit www.vermillion.com.
Investor Relations Contact:
LifeSci Advisors LLC
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vermillion-to-present-corporate-overview-at-the-canaccord-genuity-medical-technology-and-diagnostic-forum-300359440.html
SOURCE Vermillion, Inc.